EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

 

 

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. This marks the second EC approval of isatuximab in combination with a standard of care regimen in less than 12 months.

 

“As there is no cure for multiple myeloma and patients often experience disease relapse, we must persist in our pursuit for additional treatment options. Nearly 30% of patients treated with the Sarclisa regimen had a profound response with undetectable levels of multiple myeloma,” said Philippe Moreau, M.D., Department of Hematology, University Hospital of Nantes, France. “This new therapeutic regimen has the potential to become a standard of care for patients with relapsed multiple myeloma, who now have another treatment option earlier in the progression of their disease.”

 

IKEMA study

This approval is based on data from the Phase 3 IKEMA study, a randomized, multi-centre, open-label clinical trial that enrolled 302 patients with relapsed myeloma. Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 47% versus carfilzomib and dexamethasone.

 







Recent news

» Watch the webinar “COVID-19 vaccines for myeloma patients: what you need to know.”

» COVID-19 vaccines for myeloma patients: what you need to know

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.